Affordabiltiy of and Access to Medications for Multiple Sclerosis: A Policy Analysis

Document Type



Media is loading

Publication Date



Presentations: 17:54


Multiple Sclerosis (MS) is a chronic disease of the central nervous system and is the most common disabling disease of young adults. There is currently no cure for MS but there are treatments that can help to reduce the severity of relapses and delay long-term disability progression. However, treatments and medications are only as effective as they are affordable and accessible. The purpose of this study was to collect data on policy solutions that Congress can pass to allow for more affordable medications and the process of obtaining them simpler and more transparent. A qualitative research approach was taken with a focus on case study research to obtain a comprehensive examination of those living with MS, challenges of being diagnosed, and how to move forward policy that can create transparency in an otherwise opaque healthcare setting. With the passing of the Inflation Reduction Act of 2022, those living with MS who have Medicare insurance should see some relief in the next few years however, there is always more that can be done. It is my opinion that passing The Safe Step Act of 2023, the Pharmacy Benefit Manager Transparency Act of 2022, and the Prescription Pricing for the People Act of 2023 will assist in in long-term accountability and transparency. These bills, while not immediately reducing medication costs, will provide a platform for additional policy and legislative recommendations.



This document is currently not available here.